Brief: Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
19/08/2024 14:03
Aug 19 (Reuters) - Kineta Inc KA.O :
* KINETA REOPENS ENROLLMENT FOR THE VISTA-101 CLINICAL TRIAL
EVALUATING KVA12123 IN PATIENTS WITH ADVANCED SOLID TUMOR CANCER
* KINETA INC - ANTICIPATES TRIAL TO BE FULLY ENROLLED BY END
OF
2024
Source text for Eikon: ID:nGNX2jk3H6
Further company coverage: KA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study